Physician profile
Ofelia Narvasa
NPI 1558404558
$20,385.53
in general payments reported to CMS, 2019-2025
40 companies · $2,121 in 2025
The $2,121 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,287 · 2020: $2,890 · 2021: $3,872 · 2022: $3,182 · 2023: $3,498 · 2024: $2,535 · 2025: $2,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,017 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,016.50 |
| Education | $137.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,723.22 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,184.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,698.01 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Amgen INC. | $1,640.81 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $1,484.95 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $1,245.39 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $1,090.34 | 2019-2023 | |
| Esperion Therapeutics, INC. | $1,083.58 | 2021-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,064.62 | 2019-2025 | Xifaxan |
| Pfizer INC. | $957.44 | 2019-2025 | |
| Abbvie INC. | $823.76 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $525.54 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $500.11 | 2019-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $429.02 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $367.48 | 2019-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ofelia Narvasa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.